<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02326805</url>
  </required_header>
  <id_info>
    <org_study_id>NCI-2014-02556</org_study_id>
    <secondary_id>NCI-2014-02556</secondary_id>
    <secondary_id>AZ027</secondary_id>
    <secondary_id>HHSN2612012000311</secondary_id>
    <secondary_id>N01-CN-2012-00031</secondary_id>
    <secondary_id>1410547210</secondary_id>
    <secondary_id>UAZ2014-03-01</secondary_id>
    <secondary_id>N01CN00031</secondary_id>
    <secondary_id>P30CA023074</secondary_id>
    <nct_id>NCT02326805</nct_id>
  </id_info>
  <brief_title>PROSTVAC (PSA-TRICOM) in Preventing Disease Progression in Patients With Localized Prostate Cancer Undergoing Active Surveillance</brief_title>
  <official_title>Phase II Randomized, Placebo-Controlled Trial of PROSTVAC (PSA-TRICOM) in Patients With Clinically Localized Prostate Cancer Undergoing Active Surveillance</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This randomized phase II trial studies how well PROSTVAC (prostate-specific antigen&#xD;
      [PSA]-TRICOM) works in preventing disease progression in patients with prostate cancer&#xD;
      undergoing active surveillance. Vaccines made from a person's tumor cells may help the body&#xD;
      build an effective immune response to kill tumor cells that express PSA.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. To determine the effect of rilimogene-galvacirepvec (PROSTVAC) on the change (from pre to&#xD;
      post-intervention) in CD8+ positive cells in the stroma adjacent to tumor and within the&#xD;
      malignant portion of the prostate biopsies.&#xD;
&#xD;
      II. To determine the effect of PROSTVAC on the change in CD4+ positive cells in the stroma&#xD;
      adjacent to tumor and within the malignant portion of the prostate biopsies.&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I. To assess the effect of PROSTVAC on PD-L1 positive cells in the stroma adjacent to tumor&#xD;
      and within the malignant portion of the prostate biopsies.&#xD;
&#xD;
      II. To assess the correlation between the change in CD8+ and the change in PSA. III. To&#xD;
      assess the effect of PROSTVAC on CD8+, CD4+, and PD-L1 positive cells in the benign portion&#xD;
      of the prostate biopsies.&#xD;
&#xD;
      IV. To assess the effect of PROSTVAC on the change in PSA. V. To assess the effect of&#xD;
      PROSTVAC on tumor grade (Gleason score). VI. To assess the effect of PROSTVAC on tumor extent&#xD;
      (percent of positive random biopsy cores).&#xD;
&#xD;
      VII. To compare the proportion of men on the two study arms with no cancer on&#xD;
      post-intervention biopsy.&#xD;
&#xD;
      VIII. To assess the effect of PROSTVAC on the size of the dominant lesion on magnetic&#xD;
      resonance imaging (MRI) (largest histopathologically confirmed lesion) in the subgroup of&#xD;
      patients with MRIs pre and postintervention.&#xD;
&#xD;
      IX. To assess the effect of PROSTVAC on circulating 15-Mer PSA-specific, MUC-1 and&#xD;
      Brachyury-specific T cells.&#xD;
&#xD;
      X. To assess the effect of PROSTVAC on soluble antibodies to tumor-associated antigens.&#xD;
&#xD;
      XI. To assess the immunologic effects of PROSTVAC in prostate tissue using multiplex&#xD;
      immunofluorescence.&#xD;
&#xD;
      XII. To assess the safety and feasibility of PROSTVAC in the active surveillance population.&#xD;
&#xD;
      XIII. To assess the effect of PROSTVAC on lower urinary tract symptoms (LUTS) in the active&#xD;
      surveillance population.&#xD;
&#xD;
      OUTLINE: Patients are randomized to 1 of 2 treatment arms.&#xD;
&#xD;
      ARM I: Patients receive rilimogene-galvacirepvec subcutaneously (SC) at baseline and on days&#xD;
      14, 28, 56, 84, 112, and 140.&#xD;
&#xD;
      ARM II: Patients receive placebo SC at baseline and on days 14, 28, 56, 84, 112, and 140.&#xD;
&#xD;
      After completion of study treatment, patients are followed up for 30 days and then at 6&#xD;
      months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">June 3, 2015</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Actual">November 30, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in CD8+ Positive Cells in the Stroma Adjacent to Tumor and Within the Malignant Portion of the Prostate Biopsies</measure>
    <time_frame>Baseline to up to 14 days after the last dose</time_frame>
    <description>change (pre to post-intervention) in CD8+ positive cells in the stroma adjacent to tumor and within the malignant portion of the prostate biopsies.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in CD4+ Positive Cells in the Stroma Adjacent to Tumor and Within the Malignant Portion of the Prostate Biopsies</measure>
    <time_frame>Baseline to up to 14 days after the last dose</time_frame>
    <description>change (pre to post-intervention) in CD4+ positive cells in the stroma adjacent to tumor and within the malignant portion of the prostate biopsies.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in PD-L1 Positive Cells in the Stroma Adjacent to Tumor and Within the Malignant Portion of the Prostate Biopsies</measure>
    <time_frame>Baseline to 6 months post-intervention</time_frame>
    <description>A two-sided two-sample t test at a significance level of 5% will be performed to compare the rilimogene-galvacirepvec and placebo groups. A subgroup analysis will be performed to compare the change in PD-L1 positive cells between study groups in specimens collected by targeted biopsy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Prostate-specific Antigen (PSA)</measure>
    <time_frame>Baseline to 6 months post-intervention</time_frame>
    <description>Pearson correlation coefficient will be derived to evaluate the correlation between the change in CD8+ and the change in PSA for participants treated with rilimogene-galvacirepvec.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in CD8+ Positive Cells in the Benign Portion of the Prostate Biopsies</measure>
    <time_frame>Baseline to up to 14 days after the last dose</time_frame>
    <description>A two-sided two-sample t test at a significance level of 5% will be performed to compare the rilimogene-galvacirepvec and placebo groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in CD4+ Positive Cells in the Benign Portion of the Prostate Biopsies</measure>
    <time_frame>Baseline to up to 14 days after the last dose</time_frame>
    <description>A two-sided two-sample t test at a significance level of 5% will be performed to compare the rilimogene-galvacirepvec and placebo groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in PD-L1 Positive Cells in the Benign Portion of the Prostate Biopsies</measure>
    <time_frame>Baseline to up to 14 days after the last dose</time_frame>
    <description>A two-sided two-sample t test at a significance level of 5% will be performed to compare the rilimogene-galvacirepvec and placebo groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tumor Grade Progression</measure>
    <time_frame>Baseline to up to 30 days after the last dose</time_frame>
    <description>Assessed by Gleason score. A two-sided two-sample t test at a significance level of 5% will be performed to compare the rilimogene-galvacirepvec and placebo groups. Fisher's exact test will be performed to compare the proportion of patients with no cancer on the post-intervention biopsy and the proportion of men with an increase in Gleason score to &gt;= 4+3 from baseline to post-intervention biopsy between the two groups. Will be evaluated in the subgroup of patients in whom magnetic resonance imaging (MRI)-targeted biopsies were obtained pre- and post-intervention</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Tumor Extent</measure>
    <time_frame>Baseline to up to 30 days after the last dose</time_frame>
    <description>A two-sided two-sample t test at a significance level of 5% will be performed to compare the rilimogene-galvacirepvec and placebo groups. Fisher's exact test will be performed to compare the change in tumor extent and the proportion of men with an increase in Gleason score to &gt;/= 4+3 between the two groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Men With no Cancer in the Post-intervention Biopsy Between Participants Treated With Rilimogene-galvacirepvec and Those Treated With Placebo</measure>
    <time_frame>Up to 14 days after the last dose</time_frame>
    <description>This analysis will utilize all biopsy data, i.e., from random and target biopsy cores. Fisher's exact test will be performed to compare the proportion of patients with no cancer on the post-intervention biopsy and the proportion of men with an increase in Gleason score to &gt;= 4+3 between the two groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Size of Dominant MRI Lesion</measure>
    <time_frame>Up to 6 months post-intervention</time_frame>
    <description>A two-sided two-sample t test at a significance level of 5% will be performed to compare the rilimogene-galvacirepvec and placebo groups. Fisher's exact test will be performed to compare the size of dominant MRI lesion and the proportion of men with an increase in Gleason score to &gt;/= 4+3 between the two groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Adverse Events Identified Using the National Cancer Institute Common Terminology Criteria for Adverse Events Version 4.0</measure>
    <time_frame>Up to 30 days after the last dose</time_frame>
    <description>Descriptive statistics of the type and frequency of all adverse events will be generated, including 95% confidence intervals. For each type of the adverse events, a Fisher's exact test will be performed to compare the frequency of the adverse event between the two groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Circulating 15-Mer PSA-specific T Cells</measure>
    <time_frame>Baseline to up to 14 days after the last dose</time_frame>
    <description>A two-sided two-sample t test at a significance level of 5% will be performed to compare the rilimogene-galvacirepvec and placebo groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Soluble Antibodies to Tumor-associated Antigens</measure>
    <time_frame>Baseline to up to 14 days after the last dose</time_frame>
    <description>A two-sided two-sample t test at a significance level of 5% will be performed to compare the rilimogene-galvacirepvec and placebo groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunologic Effects of Rilimogene-galvacirepvec on the Target Organ Using Multiplex Immunofluorescence</measure>
    <time_frame>Up to 14 days after the last dose</time_frame>
    <description>A two-sided two-sample t test at a significance level of 5% will be performed to compare the rilimogene-galvacirepvec and placebo groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in International Prostate Symptom Score</measure>
    <time_frame>Baseline to up to 6 months post-intervention</time_frame>
    <description>A two-sided two-sample t test at a significance level of 5% will be performed to compare the rilimogene-galvacirepvec and placebo groups.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">154</enrollment>
  <condition>Stage I Prostate Adenocarcinoma AJCC v7</condition>
  <condition>Stage II Prostate Adenocarcinoma AJCC v7</condition>
  <arm_group>
    <arm_group_label>Arm I (rilimogene-galvacirepvec)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive rilimogene-galvacirepvec SC at baseline and on days 14, 28, 56, 84, 112, and 140.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm II (placebo)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients receive placebo SC at baseline and on days 14, 28, 56, 84, 112, and 140.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Laboratory Biomarker Analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Arm I (rilimogene-galvacirepvec)</arm_group_label>
    <arm_group_label>Arm II (placebo)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo Administration</intervention_name>
    <description>Given SC</description>
    <arm_group_label>Arm II (placebo)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Rilimogene Galvacirepvec</intervention_name>
    <description>Given SC</description>
    <arm_group_label>Arm I (rilimogene-galvacirepvec)</arm_group_label>
    <other_name>PROSTVAC</other_name>
    <other_name>Prostvac-V</other_name>
    <other_name>Recombinant Vaccinia-PSA(L155)-TRICOM Vaccine</other_name>
    <other_name>Recombinant Vaccinia-PSA(L155)/TRICOM</other_name>
    <other_name>Recombinant Vaccinia-PSA(L155)/TRICOM Vaccine</other_name>
    <other_name>rVaccinia-Prostate-Specific Antigen/TRICOM Vaccine</other_name>
    <other_name>rVaccinia-PSA(L155)-TRICOM Vaccine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Biopsy-proven (consisting of &gt;= 10 tissue cores) adenocarcinoma of the prostate with&#xD;
             cancer present in at least one biopsy core, either random or targeted, in the most&#xD;
             recent biopsy&#xD;
&#xD;
               -  All prior biopsies must meet the following: =&lt; 50% of the total number of random&#xD;
                  biopsy cores positive for cancer&#xD;
&#xD;
               -  Gleason score =&lt; (3+4)&#xD;
&#xD;
          -  Clinical stage =&lt; T2a by digital rectal exam (DRE)&#xD;
&#xD;
          -  Biopsies performed at outside institutions should have Gleason score confirmed at the&#xD;
             study site by a genitourinary (GU) pathologist to ensure eligibility&#xD;
&#xD;
          -  Pre-intervention biopsy tissue (most proximal to enrollment) with sufficient tumor&#xD;
             tissue to cut 5-10 unstained slides confirmed to be available upon request&#xD;
&#xD;
          -  Screening serum PSA &lt; 20 ng/mL; for men treated with 5-alpha-reductase inhibitors&#xD;
             (e.g., finasteride, dutasteride), PSA needs to be &lt; 10 ng/mL&#xD;
&#xD;
          -  Neutrophil count &gt;= 1,200/mm^3 (&gt;= 1.2 k/uL)&#xD;
&#xD;
          -  Stable platelet count &gt;= 75,000/mm^3 (&gt;= 75 k/uL)&#xD;
&#xD;
          -  Bilirubin =&lt; 1.5 mg/dL (or =&lt; 3.0 mg/dL for patients with Gilbert's syndrome)&#xD;
&#xD;
          -  Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =&lt; 2.5 x upper&#xD;
             limit of normal (ULN)&#xD;
&#xD;
          -  Serum creatinine =&lt; 1.5 x ULN&#xD;
&#xD;
          -  Karnofsky &gt;= 70%&#xD;
&#xD;
          -  Must agree to use medically acceptable barrier and/or chemical method of contraception&#xD;
             while on study and for at least one month following the last vaccine injection; should&#xD;
             a participant's partner become pregnant or suspect she is pregnant while the&#xD;
             participant is participating in this study, the study physician should be informed&#xD;
             immediately; in the event a participant's partner becomes pregnant, the study sponsor&#xD;
             may request additional information regarding the course of the pregnancy and if the&#xD;
             pregnancy is carried to term, the birth of the child (i.e., the outcome of the&#xD;
             pregnancy)&#xD;
&#xD;
          -  Ability to understand and the willingness to sign a written informed consent document&#xD;
&#xD;
          -  No planned prostate biopsies during the intervention until after the post-intervention&#xD;
             biopsy&#xD;
&#xD;
          -  Men on stable doses of 5-alpha reductase inhibitors are eligible as long as there is&#xD;
             no planned dose change while on study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Have had prior treatment for prostate cancer by surgery, irradiation, local ablative&#xD;
             (i.e., cryosurgery or high-intensity focused ultrasound), or androgen-deprivation&#xD;
             therapy&#xD;
&#xD;
          -  Patients who have prostate cancer with distant metastases&#xD;
&#xD;
          -  Have undergone treatment of hormone therapy, immunotherapy, chemotherapy and/or&#xD;
             radiation for any malignancies within the past 2 years&#xD;
&#xD;
          -  Uncontrolled intermittent illnesses or medical conditions which, in the opinion of the&#xD;
             treating physician, would make this protocol unreasonably hazardous for the patient;&#xD;
             such illnesses/conditions may include, but are not limited to, ongoing or active&#xD;
             infection, symptomatic congestive heart failure, unstable angina pectoris, symptomatic&#xD;
             or unstable cardiac arrhythmia, or psychiatric illness/social situations that would&#xD;
             limit compliance with study requirements&#xD;
&#xD;
          -  Positive for human immunodeficiency virus (HIV) or active infections for hepatitis B,&#xD;
             and/or hepatitis C, based on medical history&#xD;
&#xD;
          -  Prior solid organ or bone marrow transplant&#xD;
&#xD;
          -  Immunodeficiency or splenectomy&#xD;
&#xD;
          -  Chronic immunosuppressive therapy within 30 days of screening&#xD;
&#xD;
          -  Inflammatory eye disease requiring steroid treatment within 28 days of screening&#xD;
&#xD;
          -  Chronic administration (defined as daily or every other day for continued use &gt; 14&#xD;
             days) of systemic corticosteroids within 28 days of the first planned dose of&#xD;
             PROSTVAC-V/F; use of inhaled steroids, nasal sprays, and topical creams for small body&#xD;
             areas is allowed&#xD;
&#xD;
          -  History of or active autoimmune disease including but not limited to autoimmune&#xD;
             neutropenia, thrombocytopenia, or hemolytic anemia, systemic lupus erythematosus,&#xD;
             Sjogren's syndrome, scleroderma, myasthenia gravis, Goodpasture's syndrome; persons&#xD;
             with vitiligo are not excluded; Persons with well-controlled autoimmune&#xD;
             endocrinopathies, e.g., diabetes mellitus, Graves' disease, Hashimoto's thyroiditis,&#xD;
             Addison's disease are not excluded; persons with well-controlled rheumatoid arthritis,&#xD;
             psoriatic arthritis and polymyalgia rheumatica are not excluded&#xD;
&#xD;
          -  Known allergy to eggs, egg products&#xD;
&#xD;
          -  Prior or concurrent eczema or other eczemoid skin disorders or active skin condition&#xD;
             (acute, chronic, or exfoliative) that disrupts the epidermis; persons with psoriasis&#xD;
             are not excluded except in cases of:&#xD;
&#xD;
               -  any active lesion&#xD;
&#xD;
               -  any active lesion in the previous 6 months that required treatment, either&#xD;
                  systemic or topical&#xD;
&#xD;
               -  any prior episode, at any time, extensive enough or severe enough as to require&#xD;
                  systemic treatment&#xD;
&#xD;
          -  Previous adverse reactions to smallpox vaccination&#xD;
&#xD;
          -  Unable to avoid close contact or household contact with the following high-risk&#xD;
             individuals for three weeks after the day 1 vaccination or until the vaccination site&#xD;
             heals completely: (a) children =&lt; 3 years of age, (b) pregnant or nursing women, (c)&#xD;
             individuals with prior or concurrent extensive eczema or other eczemoid skin&#xD;
             disorders, (d) individuals with other acute, chronic, or exfoliative skin condition,&#xD;
             or (e) immunocompromised or immunosuppressed persons (by disease or therapy)&#xD;
&#xD;
          -  Participants may not be receiving any other investigational agents&#xD;
&#xD;
          -  History of allergic reactions attributed to compounds of similar chemical or biologic&#xD;
             composition of PROSTVAC&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John K Parsons</last_name>
    <role>Principal Investigator</role>
    <affiliation>The University of Arizona Medical Center-University Campus</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>USC / Norris Comprehensive Cancer Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cedars Sinai Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hoag Memorial Hospital</name>
      <address>
        <city>Newport Beach</city>
        <state>California</state>
        <zip>92663</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UC Irvine Health/Chao Family Comprehensive Cancer Center</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California San Diego</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins Bayview Medical Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NCI - Center for Cancer Research</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>December 24, 2014</study_first_submitted>
  <study_first_submitted_qc>December 24, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 30, 2014</study_first_posted>
  <results_first_submitted>September 9, 2021</results_first_submitted>
  <results_first_submitted_qc>October 6, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">November 2, 2021</results_first_posted>
  <disposition_first_submitted>December 3, 2019</disposition_first_submitted>
  <disposition_first_submitted_qc>December 4, 2019</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">December 16, 2019</disposition_first_posted>
  <last_update_submitted>October 6, 2021</last_update_submitted>
  <last_update_submitted_qc>October 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
    <mesh_term>Adenocarcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metronidazole</mesh_term>
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol, Statistical Analysis Plan, and Informed Consent Form</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>September 26, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/05/NCT02326805/Prot_SAP_ICF_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Arm I (Rilimogene-galvacirepvec)</title>
          <description>Patients receive rilimogene-galvacirepvec SC at baseline and on days 14, 28, 56, 84, 112, and 140.&#xD;
Laboratory Biomarker Analysis: Correlative studies&#xD;
Rilimogene Galvacirepvec: Given SC</description>
        </group>
        <group group_id="P2">
          <title>Arm II (Placebo)</title>
          <description>Patients receive placebo SC at baseline and on days 14, 28, 56, 84, 112, and 140.&#xD;
Laboratory Biomarker Analysis: Correlative studies&#xD;
Placebo Administration: Given SC</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="106"/>
                <participants group_id="P2" count="48"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="103"/>
                <participants group_id="P2" count="47"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Arm I (Rilimogene-galvacirepvec)</title>
          <description>Patients receive rilimogene-galvacirepvec SC at baseline and on days 14, 28, 56, 84, 112, and 140.&#xD;
Laboratory Biomarker Analysis: Correlative studies&#xD;
Rilimogene Galvacirepvec: Given SC</description>
        </group>
        <group group_id="B2">
          <title>Arm II (Placebo)</title>
          <description>Patients receive placebo SC at baseline and on days 14, 28, 56, 84, 112, and 140.&#xD;
Laboratory Biomarker Analysis: Correlative studies&#xD;
Placebo Administration: Given SC</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="106"/>
            <count group_id="B2" value="48"/>
            <count group_id="B3" value="154"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="65" spread="7"/>
                    <measurement group_id="B2" value="64" spread="8"/>
                    <measurement group_id="B3" value="64" spread="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="106"/>
                    <measurement group_id="B2" value="48"/>
                    <measurement group_id="B3" value="154"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="98"/>
                    <measurement group_id="B2" value="45"/>
                    <measurement group_id="B3" value="143"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="91"/>
                    <measurement group_id="B2" value="43"/>
                    <measurement group_id="B3" value="134"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="106"/>
                    <measurement group_id="B2" value="48"/>
                    <measurement group_id="B3" value="154"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in CD8+ Positive Cells in the Stroma Adjacent to Tumor and Within the Malignant Portion of the Prostate Biopsies</title>
        <description>change (pre to post-intervention) in CD8+ positive cells in the stroma adjacent to tumor and within the malignant portion of the prostate biopsies.</description>
        <time_frame>Baseline to up to 14 days after the last dose</time_frame>
        <population>Participants with tumor present in tissue sections from both the pre and post-intervention biopsies</population>
        <group_list>
          <group group_id="O1">
            <title>Arm I (Rilimogene-galvacirepvec)</title>
            <description>Patients receive rilimogene-galvacirepvec SC at baseline and on days 14, 28, 56, 84, 112, and 140.&#xD;
Laboratory Biomarker Analysis: Correlative studies&#xD;
Rilimogene Galvacirepvec: Given SC</description>
          </group>
          <group group_id="O2">
            <title>Arm II (Placebo)</title>
            <description>Patients receive placebo SC at baseline and on days 14, 28, 56, 84, 112, and 140.&#xD;
Laboratory Biomarker Analysis: Correlative studies&#xD;
Placebo Administration: Given SC</description>
          </group>
        </group_list>
        <measure>
          <title>Change in CD8+ Positive Cells in the Stroma Adjacent to Tumor and Within the Malignant Portion of the Prostate Biopsies</title>
          <description>change (pre to post-intervention) in CD8+ positive cells in the stroma adjacent to tumor and within the malignant portion of the prostate biopsies.</description>
          <population>Participants with tumor present in tissue sections from both the pre and post-intervention biopsies</population>
          <units>number of positive cells per mm^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="72"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.2" spread="151.4"/>
                    <measurement group_id="O2" value="-6.9" spread="154"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in CD4+ Positive Cells in the Stroma Adjacent to Tumor and Within the Malignant Portion of the Prostate Biopsies</title>
        <description>change (pre to post-intervention) in CD4+ positive cells in the stroma adjacent to tumor and within the malignant portion of the prostate biopsies.</description>
        <time_frame>Baseline to up to 14 days after the last dose</time_frame>
        <population>Participants with tumor present on the tissue sections from both the pre and post-intervention biopsies were included in the analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Arm I (Rilimogene-galvacirepvec)</title>
            <description>Patients receive rilimogene-galvacirepvec SC at baseline and on days 14, 28, 56, 84, 112, and 140.&#xD;
Laboratory Biomarker Analysis: Correlative studies&#xD;
Rilimogene Galvacirepvec: Given SC</description>
          </group>
          <group group_id="O2">
            <title>Arm II (Placebo)</title>
            <description>Patients receive placebo SC at baseline and on days 14, 28, 56, 84, 112, and 140.&#xD;
Laboratory Biomarker Analysis: Correlative studies&#xD;
Placebo Administration: Given SC</description>
          </group>
        </group_list>
        <measure>
          <title>Change in CD4+ Positive Cells in the Stroma Adjacent to Tumor and Within the Malignant Portion of the Prostate Biopsies</title>
          <description>change (pre to post-intervention) in CD4+ positive cells in the stroma adjacent to tumor and within the malignant portion of the prostate biopsies.</description>
          <population>Participants with tumor present on the tissue sections from both the pre and post-intervention biopsies were included in the analysis</population>
          <units>number of positive cells per mm^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="69"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.6" spread="166.7"/>
                    <measurement group_id="O2" value="5.8" spread="261.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in PD-L1 Positive Cells in the Stroma Adjacent to Tumor and Within the Malignant Portion of the Prostate Biopsies</title>
        <description>A two-sided two-sample t test at a significance level of 5% will be performed to compare the rilimogene-galvacirepvec and placebo groups. A subgroup analysis will be performed to compare the change in PD-L1 positive cells between study groups in specimens collected by targeted biopsy.</description>
        <time_frame>Baseline to 6 months post-intervention</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Prostate-specific Antigen (PSA)</title>
        <description>Pearson correlation coefficient will be derived to evaluate the correlation between the change in CD8+ and the change in PSA for participants treated with rilimogene-galvacirepvec.</description>
        <time_frame>Baseline to 6 months post-intervention</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in CD8+ Positive Cells in the Benign Portion of the Prostate Biopsies</title>
        <description>A two-sided two-sample t test at a significance level of 5% will be performed to compare the rilimogene-galvacirepvec and placebo groups.</description>
        <time_frame>Baseline to up to 14 days after the last dose</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in CD4+ Positive Cells in the Benign Portion of the Prostate Biopsies</title>
        <description>A two-sided two-sample t test at a significance level of 5% will be performed to compare the rilimogene-galvacirepvec and placebo groups.</description>
        <time_frame>Baseline to up to 14 days after the last dose</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in PD-L1 Positive Cells in the Benign Portion of the Prostate Biopsies</title>
        <description>A two-sided two-sample t test at a significance level of 5% will be performed to compare the rilimogene-galvacirepvec and placebo groups.</description>
        <time_frame>Baseline to up to 14 days after the last dose</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Tumor Grade Progression</title>
        <description>Assessed by Gleason score. A two-sided two-sample t test at a significance level of 5% will be performed to compare the rilimogene-galvacirepvec and placebo groups. Fisher's exact test will be performed to compare the proportion of patients with no cancer on the post-intervention biopsy and the proportion of men with an increase in Gleason score to &gt;= 4+3 from baseline to post-intervention biopsy between the two groups. Will be evaluated in the subgroup of patients in whom magnetic resonance imaging (MRI)-targeted biopsies were obtained pre- and post-intervention</description>
        <time_frame>Baseline to up to 30 days after the last dose</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Tumor Extent</title>
        <description>A two-sided two-sample t test at a significance level of 5% will be performed to compare the rilimogene-galvacirepvec and placebo groups. Fisher's exact test will be performed to compare the change in tumor extent and the proportion of men with an increase in Gleason score to &gt;/= 4+3 between the two groups.</description>
        <time_frame>Baseline to up to 30 days after the last dose</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Men With no Cancer in the Post-intervention Biopsy Between Participants Treated With Rilimogene-galvacirepvec and Those Treated With Placebo</title>
        <description>This analysis will utilize all biopsy data, i.e., from random and target biopsy cores. Fisher's exact test will be performed to compare the proportion of patients with no cancer on the post-intervention biopsy and the proportion of men with an increase in Gleason score to &gt;= 4+3 between the two groups.</description>
        <time_frame>Up to 14 days after the last dose</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Size of Dominant MRI Lesion</title>
        <description>A two-sided two-sample t test at a significance level of 5% will be performed to compare the rilimogene-galvacirepvec and placebo groups. Fisher's exact test will be performed to compare the size of dominant MRI lesion and the proportion of men with an increase in Gleason score to &gt;/= 4+3 between the two groups.</description>
        <time_frame>Up to 6 months post-intervention</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Adverse Events Identified Using the National Cancer Institute Common Terminology Criteria for Adverse Events Version 4.0</title>
        <description>Descriptive statistics of the type and frequency of all adverse events will be generated, including 95% confidence intervals. For each type of the adverse events, a Fisher's exact test will be performed to compare the frequency of the adverse event between the two groups.</description>
        <time_frame>Up to 30 days after the last dose</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Circulating 15-Mer PSA-specific T Cells</title>
        <description>A two-sided two-sample t test at a significance level of 5% will be performed to compare the rilimogene-galvacirepvec and placebo groups.</description>
        <time_frame>Baseline to up to 14 days after the last dose</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Soluble Antibodies to Tumor-associated Antigens</title>
        <description>A two-sided two-sample t test at a significance level of 5% will be performed to compare the rilimogene-galvacirepvec and placebo groups.</description>
        <time_frame>Baseline to up to 14 days after the last dose</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Immunologic Effects of Rilimogene-galvacirepvec on the Target Organ Using Multiplex Immunofluorescence</title>
        <description>A two-sided two-sample t test at a significance level of 5% will be performed to compare the rilimogene-galvacirepvec and placebo groups.</description>
        <time_frame>Up to 14 days after the last dose</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in International Prostate Symptom Score</title>
        <description>A two-sided two-sample t test at a significance level of 5% will be performed to compare the rilimogene-galvacirepvec and placebo groups.</description>
        <time_frame>Baseline to up to 6 months post-intervention</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>30 days after the last study dose was given</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Arm I (Rilimogene-galvacirepvec)</title>
          <description>Patients receive rilimogene-galvacirepvec SC at baseline and on days 14, 28, 56, 84, 112, and 140.&#xD;
Laboratory Biomarker Analysis: Correlative studies&#xD;
Rilimogene Galvacirepvec: Given SC</description>
        </group>
        <group group_id="E2">
          <title>Arm II (Placebo)</title>
          <description>Patients receive placebo SC at baseline and on days 14, 28, 56, 84, 112, and 140.&#xD;
Laboratory Biomarker Analysis: Correlative studies&#xD;
Placebo Administration: Given SC</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="103" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="48" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="43" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Injection site reaction</sub_title>
                <counts group_id="E1" subjects_affected="95" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="45" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Flu like syndromes</sub_title>
                <counts group_id="E1" subjects_affected="63" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="30" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory infection</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Bruising</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>White blood cell decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal and urinary disorders - others</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Sore throat</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash maculo-papular</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Skin and subcutaneous tissue disorders - other</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Sherry Chow, PhD</name_or_title>
      <organization>University of Arizona</organization>
      <phone>520-626-3358</phone>
      <email>schow@azcc.arizona.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

